<DOC>
	<DOCNO>NCT02001506</DOCNO>
	<brief_summary>Various regimen schedule neoadjuvant chemotherapy regimen investigate sequential treatment anthracyclines follow taxanes , show superior pathologic complete respone ( pCR ) rate ( NSABP-B27 study ) widely use . Considering proven efficacy tolerable toxicity 3 cycle FEC follow 3 cycle Docetaxel ( FEC3-D3 ) compare FEC 6 cycle adjuvant chemotherapy ( PACS 01 trial ) , use FEC3-D3 regimen neoadjuvant set feasible acceptable efficacy reduce duration neoadjuvant chemotherapy .</brief_summary>
	<brief_title>Neoadjuvant Chemotherapy 6 Cycles v 8 Cycles Node Positve Breast Cancer</brief_title>
	<detailed_description>To investigate feasibility FEC3-D3 regimen neoadjuvant set term comparable efficacy short duration across subtypes .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Performance status 0 1 Clinically stage 2 3 histologically proven lymph node involvement Tumor lymph node great 1.5 cm Pregnancy lactation Prior chemotherapy radiotherapy malignancy Documented history cardiac disease contraindicate anthracyclines Currently active infection</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>neoadjuvant</keyword>
	<keyword>different number chemotherapy cycle</keyword>
</DOC>